Physician profile
Stacy Lynn Sharp
NPI 1407509219
$2,930.65
in general payments reported to CMS, 2019-2025
28 companies · $946 in 2025
The $946 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $718 · 2023: $536 · 2024: $730 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $682.12 | 2022-2025 | Caplyta |
| Abbvie INC. | $472.03 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.93 | 2022-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $239.72 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $128.71 | 2022-2025 | Rexulti |
| Pfizer INC. | $114.21 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.28 | 2022 | |
| Lilly USA, LLC | $97.10 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $95.81 | 2022-2025 | Evenity, Prolia, Repatha |
| Axsome Therapeutics, INC. | $94.98 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $94.44 | 2025 | Wegovy |
| Neurocrine Biosciences, INC. | $64.60 | 2022-2024 | Ingrezza |
| Exact Sciences Corporation | $63.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $47.77 | 2022-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.41 | 2022-2025 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $44.62 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.10 | 2022-2023 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $34.34 | 2024-2025 | Veozah |
| Verona Pharma, INC. | $34.23 | 2025 | Ohtuvayre |
| Nestle Healthcare Nutrition INC. | $24.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.31 | 2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $19.97 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $15.88 | 2022 | |
| Phadia US INC. | $15.18 | 2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $14.72 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $14.54 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $14.22 | 2022 | |
| Lundbeck LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.